Bicara Therapeutics Inc. Common Stock (BCAX) NASDAQ

Currency In USD

Bicara Therapeutics Inc. Common Stock

Address

116 Huntington Avenue

Boston, MA 02116

United States of America (the)

Phone

617-468-4219

Website

https://www.bicara.com

Sector

Healthcare

Industry

Biotechnology

Employees

103

First IPO Date

September 13, 2024

Key Executives

Name	Title	Pay	Year Born
Claire Mazumdar Clemon	Chief Executive Officer & Director	927,688	1990
David Raben	Chief Medical Officer	709,164	1964
Ryan Cohlhepp	President, Chief Operating Officer & Director	858,400	1977
Ivan Hyep	CFO & Treasurer	915,375	1985
Angela Windt	Vice President & Head of Regulatory Affairs	0	N/A
Jean-Paul Rodrique	Senior Vice President & Global Head of Quality Assurance	0	N/A
Gary Bostanxhi	Vice President of Finance & Controller	0	N/A
Rachel Salazar	SVP of R&D Strategy and Operations	0	N/A
Lara S. Meisner	Chief Legal Officer, Compliance Officer & Corporate Secretary	0	1972
Pauline Dufresne	Chief People Officer	0	N/A
Rachel Frank	Vice President of Investor Relations and Corporate Communications	0	N/A
Sathish Hasige	Senior Vice President and Head of Technical Operations & Supply Chain	0	N/A
Jeltje Schulten	Senior Vice President of Clinical & Medical Affairs	0	N/A

Description

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.